A new methodology for the detection of functional response of peripheral blood mononuclear cells against breast cancer (BC) antigens was developed. The method is based on cellular enzymatic activity measurements, using a fluorogenic substrate. We used this method to estimate the kinetic activity of lymphocytes derived from cancer patients and healthy donors. The aim of the study was to determine a possible correlation between the basic characteristics (Km and Vmax) of biochemical enzymatic reactions in live peripheral white mononuclear cells and common clinical-pathological characteristics in BC patients. Our method shows that the enzymatic activity, upon interaction with mitogen or tumor antigens, of the peripheral blood cells in BC patients is different from the enzymatic reactions in healthy individuals. This holds true in the early stages, and the difference persists throughout all of the stages of the disease. This difference is manifested, primarily, by an increase in the Km values after cell incubation with tumor tissue. It was also demonstrated that higher Km values of tumor tissue-activated peripheral blood mononuclear cells are associated with a better prognostic status of the BC patients (lymph node-negative tumors, hormone receptor preservation, and the absence of Her-2/neu protein overexpression). Thus, the present methodology may serve as an additional criterion for prognosis and monitoring, both in BC patients, and in individuals associated with high cancer risk.

Because early detection of cancer is now recognized to greatly contribute to more successful treatment and, thus, survival of cancer patients (1), numerous attempts have been made to develop sensitive and specific assays for diagnosis, monitoring, and surveillance of breast cancer (BC; Refs. 2, 3, 4). However, the methods of clinical screening and diagnosis (in particular, the screening mammography) are limited in their prognostic capacity due to significant rates of false results. A great number of markers (tumor size, lymph node involvement, tumor cell differentiation patterns, nuclear grade, DNA S phase profiles, the estrogen and progesterone receptor status, and Her-2/neu protein overexpression) used currently for detection and prognosis of BC are only suitable for predicting the life quality of patients who already undergo advanced stages of the disease. These markers are characteristic of advanced tumors and advanced anticancer responses, and may be obtained only after surgery (5, 6).

The study of the multistep process of BC tumorigenesis demonstrated a sustained, successive accumulation of genetic, biochemical, and immune abnormalities during the disease progression before the appearance of clinically determinable tumors (7, 8, 9, 10, 11, 12, 13). Because these qualitative and quantitative changes precede the cancer clinical manifestations there has been an ongoing effort to use them for early cancer detection.

The conditions of the lymphocyte membrane and cytoplasm differ structurally and functionally between individuals with and without malignancies. Antigenic stimulation by the classic mitogens phytohemagglutinin (PHA) and concanavalin A, as well as by specific tumor-associated antigens induces changes in the structure of the cytoplasmic matrix, detectable via fluorescein diacetate (FDA) staining (14, 15, 16, 17, 18). Specifically, mitogenic stimulation of peripheral lymphocytes results in changes in their intracellular microviscosity, which are manifested in a characteristic kinetic behavior of FDA hydrolysis leading to an increase in the fluorescence intensity of intracellular fluorescein (19). Moreover, these changes in microviscosity precede other alterations due to activation, such as gene, receptor, and protein expression.

We have developed a novel methodology for detection of early lymphocyte activation signs based on steady state measurements of the fluorescence intensity in fluorescein-labeled peripheral blood mononuclear cells (PBMCs; Refs. 15, 19). The estimation of the kinetics of this process was conducted via the Michaelis-Menten constants. Our preliminary results have shown that early activation events, which occur upon cell incubation with and without either phytohemagglutinin or autologous tumor tissue, may be demonstrated by the general biochemical kinetic parameters (the Michaelis-Menten constant, Km, and the maximal velocity, Vmax) that display the differences in intracellular processes in the lymphocytes, related to the enzymatic activity as well as to the cell size, the cytoplasm membrane permeability, and so forth (15, 16, 19).

The aim of our study was to determine possible correlations between basic characteristics (Km and Vmax) of biochemical enzymatic reactions in live PBMCs and common clinical-pathological signs in BC patients.

#### Case Material.

Twenty eight patients with BC, 10 patients with colon cancer, and 23 healthy volunteers were examined, using our methodology of measurement and analysis of apparent Km (Michaelis-Menten constant) and Vmax values for individual cells. The blood and tissue samples were obtained from surgical departments of Assaf Harofeh Medical Center and Rabin Medical Center. The research was conducted in accordance with the principles of the Declaration of Helsinki. The pathological tumor tissue examinations were carried out by the pathology departments of these hospitals. The tumor tissue samples were kept in liquid nitrogen until their use. The clinical and histological characteristics of BC patients are shown in Table 1. We used the colon cancer patients group for the comparison of the basic enzymatic characteristics of PBMCs in patients with fundamentally different cancer types, hormone-related (BC) and hormone-unrelated (colon) tumors.

#### Cell Separation and Experimental Procedure.

Peripheral blood was collected in heparinized tubes at the time of surgery. After removing the iron-absorbing cells, the remaining mononuclear cells were separated by Ficoll-Hypaque (Sigma, St. Louis, MO) density gradient centrifugation. The cells were subsequently harvested, washed twice in PBS (pH 7.2), and resuspended in complete RPMI 1640. The rate of FDA hydrolysis by esterases was measured in PBMCs following three different treatments, after 30 min of incubation, without any stimulant, or with the standard nonspecific mitogen PHA (90 μg/ml) in PBS, or with a small piece (1 mm3) of intact unfractionized auto- or homologous tumor tissue. The autologous tumor tissue was used in the majority of patients (58%), whereas the homologous tumor tissue was used in healthy donors and in the rest of the patients.

#### Measurements.

The enzymatic hydrolysis of FDA and the intracellular accumulation of fluorescein by individual PBMCs were measured by the Individual Cell Scanner on a cell tray as described previously (18). The control of the cell uniformity was performed by microscopic examination on the cell tray developed and patented by our labs. In this tray (total capacity of 10,000 cells/tray), individual cells were separated by 20 μm in a matrix array. The remainders of the tumor tissue were removed by multiple PBS washing. Using the fluorogenic FDA substrate, we measured the kinetic parameters of esterase activity of PBMCs derived from cancer patients and healthy donors. The main kinetic characteristics Km (the Michaelis constant) and Vmax (maximal velocity) of biochemical reaction for individual cells (maximum 300 cells/patient) were calculated after repeated periodical measurements (24 times) of the same cells, which were sequentially exposed to various increasing fluorogenic substrate concentrations (0.6 μm, 1.2 μM, 2.4 μm, and 3.6 μm) of FDA in PBS staining solutions. Cells were measured six times per each substrate concentration at time intervals of ∼40 s. The time intervals for the replacement of FDA solutions were 50 s. Under the sequential FDA exposure, the fluorescent intensity slope between successive FDA concentrations was almost zero, which means that V0 dropped back to zero (18). The duration of all 24 of the measurements did not exceed 1,000 s. Damaged and dead cells, which did not show an increase in fluorescent intensity on exposure to higher concentrations of FDA, were excluded from the mathematical analysis. For each subject, six trays were used, two trays per each type of cell treatment.

#### Mathematical Calculations.

The main biochemical constants (Km and Vmax) were derived by applying the so-called Lineweaver-Burk plot, also known as the double reciprocal plot

$\frac{1}{{\nu}_{0}}\ {=}\ \frac{K_{\mathrm{m}}}{V_{\mathrm{max}}}\frac{1}{{[}S{]}}\ {+}\ \frac{1}{V_{\mathrm{max}}}$

that is relatively simple in comparison to other known methods and more suitable for the present experimental conditions (20).

All of the values are presented as average ± SE. The comparisons between groups were performed by Student’s t test.

Cells localized on the cell tray were sequentially exposed to four different FDA concentrations and scanned six times per concentration, at time intervals of ∼40 s. A representative chart of a complete measurement procedure performed on 20 individual PBMCs derived from a BC patient is shown in Fig. 1. Km and Vmax coefficients were calculated for each individual cell within the population of PBMCs after incubation with or without tumor tissue. Average Km values were found to be 1.51 ± 0.3 μm in untreated cells and 4.0 ± 1.9 μm in tumor tissue-treated cells. The corresponding Vmax values were found to be 548.7 ± 113 au in untreated cells and 587 ± 213 au in tumor tissue-treated cells. This indicates an increase of 165% in Km and 7% in Vmax on exposure of the cells to cancer tissue.

The same procedure was performed to extract mean Km and Vmax values for all of the cancer patients and healthy donors. The average Km values of untreated cells were found to be 1.73 ± 0.182 μm, 1.93 ± 0.24 μm, and 2.02 ± 0.208 μm for healthy donors, BC patients, and colon cancer patients, respectively (the Km values and corresponding Vmax values are presented in Table 2). An increase in average Km values in cancer patients in comparison with healthy donors was not distinguishable statistically (P > 0.05). However, the cell stimulation with the standard mitogen or tumor tissue revealed a difference in the cells status. The nonspecific mitogenic PHA stimulation of PBMCs increased the Km and Vmax values both in healthy donors and in cancer patients as compared with measurements of the untreated cells (Table 2). Still, the increase of Vmax values after PBMC activation by PHA in the BC patients (1094.5 ± 131.77 au) was less significant in comparison with healthy individuals (P < 0.03), whose average Vmax value amounted to 1995.58 ± 360.35 au (P < 0.00006).

Incubation of PBMCs with tumor tissue effected a change in the Km values different in cancer patients and healthy control subjects (Table 2); the Km values sharply increased (P < 0.004), as compared with untreated cells, in cancer patients (from 1.93 ± 0.24 μm to 2.95 ± 0.47 μm in BC patients, and from 2.02 ± 0.208 μm to 3.45 ± 0.72 μm in colon cancer patients), and almost did not change in healthy individuals (1.73 ± 0.182 μm in untreated cells and 1.56 ± 0.127 μm after cell incubation with tumor tissue). Alterations in the Vmax values were small in comparison with untreated cells.

Because the purpose of the present study relates primarily to the BC problematics, we studied the parameters of enzymatic reactions in different clinical-pathological groups of cancer patients, taking into account general solid tumor characteristics, histological grade, lymph node status, steroid hormone receptors (to estrogen and progesterone hormones), and HER-2/neu protein expression that shows the proliferation rate of tumor cells. The clinical and histological characteristics of BC patients are shown in Table 1.

Tumors are generally classified according to their histopathological grade. The more differentiated the tumor cells are, the better the prognosis. The present study indicated that the increase in the average Km values of PBMCs, after exposure to tumor tissue, is higher in the groups with different tumor grades as compared with that in healthy individuals (Fig. 2). However, the increase of the average Km after incubation with tumor tissue was significantly higher (P < 0.03) as compared with healthy donors, only in patients with moderately (grade 2) differentiated tumors (3.58 ± 0.75 μm and 1.56 ± 0.127 μm, respectively). We also found a statistically significant (P < 0.009) difference in Km values in untreated cells between well- (grade 1) and moderately differentiated tumors (Fig. 2).

The average Vmax value after incubation with tumor tissue did not change significantly in either healthy donors or in the general group of patients (Table 2). The analysis of the Vmax value in PBMCs after tumor tissue incubation in the different histopathologic subgroups of BC patients did not reveal any significant changes (Table 3). At the same time, incubation with the nonspecific standard mitogen PHA (Table 3) led to an increase in the average Vmax values in patients with low-differentiated tumors (from 321.5 ± 106.0 au in untreated cells to 1109.2 ± 254.9 au; P < 0.02) and well-differentiated tumors (from 224.9 ± 64.8 au to 1071.8 ± 316.9 au; P < 0.02). This increase was comparable in magnitude to that in healthy individuals (in 3.5, 4.8, and 3.1 times in low-differentiated, well-differentiated tumor groups, and healthy donors, respectively), which may indicate the preservation of the nonspecific functional competence of these cells. An increase of average Vmax values in patients with moderately differentiated tumors (from 648.6 ± 186.3 au in untreated cells to 1124.8 ± 193.9 au in PHA-incubated cells) was observed, but it was not significant in comparison with untreated cells.

The most commonly used prognostic markers for cancer patients, and particularly BC patients, are tumor size and lymph node involvement. We tested the Km and Vmax alterations in different subgroups of BC patients according to the tumor size, bearing in mind that ductal carcinoma in situ is the microinvasive breast carcinoma with a better prognosis. It was shown that there is no significant difference in average Km values between patients having ductal carcinoma in situ (1.96 ± 0.21 μm) and patients with other histological tumors (1.61 ± 0.2 μm). However, the increase in the average Km values after tumor tissue incubation was more considerable in ductal carcinoma in situ patients (4.3 ± 1.07 μm; P ≤ 0.05) than in patients with other histological BC types (2.84 ± 0.5; P < 0.04). On the other hand, there is a tendency of increase in the average Vmax values after tumor tissue incubation in ductal carcinoma in situ patients only (1282.4 ± 573.2 au in comparison with 567.1 ± 185.9 au in untreated cells).

The involvement of axillary nodes in tumor development has long been recognized as a key feature in determining prognosis for BC patients. In patients without metastases in lymph nodes, average Km values, after incubation with tumor tissue, were significantly higher as compared with untreated cells of these patients. In the subgroup of patients with lymph node involvement, no significant rise in Km after incubation with tumor tissue was observed (Table 4).

Valuable parameters for determining the prognosis for BC patients are hormone receptor levels and proto-oncogene overexpression. We investigated the alterations of the main kinetic characteristics (Km and Vmax) of the enzymatic reaction according to estrogen and progesterone receptor status (Table 4). The results indicate that in subgroups of patients with better-differentiated tumor cells (progesterone and estrogen receptor-positive tumors) average Km values were significantly higher (P < 0.05) after tumor tissue exposure compared with nonactivated cells. Apart from this, in the subgroup of patients with preserved progesterone receptors, the average Km values in untreated cells (without nonspecific or specific stimulation) were significantly higher than in patients with loss of progesterone receptors, whereas the average Vmax values in these different subgroups were not significantly different in all of the experimental conditions (data not shown).

The level of the protein Her-2/neu is known to be a marker for poor outcome and is associated with typically poor response to chemotherapy by tamoxifen. We studied the Km and Vmax in the patient subgroups dependent on the Her-2/neu protein expression. It was shown that the average Km values after incubation with tumor tissue increased significantly in comparison with untreated cells only in patients with Her-2/neu protein-negative tumors (Table 4). Vmax values were similar in these two BC patient subgroups (data not shown).

Of special interest is the use of autologous or homologous tumor tissue as the specific or nonspecific stimuli for detection of functional response against BC based on periodical measurements of antigenic lymphocyte activation of peripheral blood cells. This interest derives from the observation that autologous tumor antigen is not present in all of the patients (21). As mentioned, we used autologous tumor tissue for the major part of BC patients (58%), whereas homologous tumor tissue was used in healthy donors and in other patients. It was shown that the average Km values tended to rise after incubation with tumor tissue both in cells exposed to autologous and to homologous tumor tissue (Fig. 3). Km pattern values in the patients were higher than in healthy donors (3.51 ± 0.9 μm in patient cells after autologous tumor tissue incubation, 2.41 ± 0.49 μm in patient cells after homologous tumor tissue incubation, and 1.56 ± 0.12 μm in healthy donors after homologous tumor tissue incubation), but the difference between average Km values was statistically significant only in patients whose PBMCs were exposed to autologous tissue (P < 0.05). In patients whose lymphocytes were activated by homologous tumor tissue, the average Km values had only a tendency of increase. Although there is no statistically significant difference in Km after homologous tumor tissue exposure as compared with healthy donors, the presence of the similar tendencies of Km increase may point out to the possible similarity of the antigens causing this response or the common mechanisms involved in the activation by both autologous and homologous tumor tissue. Our present results indirectly evidence that an increase of Km values in cells incubated with autologous tumor tissue, in comparison with untreated PBMCs, may serve as a cautionary feature in the monitoring of BC patients in the postoperative period or during the periods between chemotherapy courses, whereas homologous tumor tissue can be used for screening individuals with high cancer risk.

FDA staining has been long used in studying the cellular kinetic parameters, measurement of total population, and subset characteristics, and for the estimation of different cellular physiological states, such as activation and apoptosis (19, 22, 23, 24, 25, 26, 27). It has been shown that cell populations exhibit wide heterogeneity with respect to their ability to use FDA, dependent on their type, cell cycle stage, and the cell surface status (28, 29, 30, 31). The simplicity of FDA staining and the reliability of observation make this method handy and promising. Moreover, this novel methodology, which involves the estimation of classic kinetic parameters (Km and Vmax) of enzymatic reactions in individual cells, has several additional advantages over other techniques. First of all, it provides the ability to use different increasing FDA concentrations (18) and measure repeatedly the fluorescence of the same individual living cells within a population. The staining rate, which practically reflects the conversion rate of the nonfluorescent substrate to the fluorescent product, is measured for each cell at each dye concentration, yielding a series of staining rates for the same cell. In the preliminary experiments (18), the individual cell coefficient of variance obtained in >10 successive measurement scans of a 10 × 10 cell field never exceeded 2% for fluorescent intensity. Using these data, Vmax and apparent Km values can be calculated for each cell, giving the distribution of Km and Vmax of the entire population. These technique and analytic tools are applied to trace differences in distributions of Km and Vmax over a population of individual cells. Secondly, unfractionized tumor is used for the induction of anticancer functional response. It has been known that autologous tumor antigens, even if they are expressed on the tumor cell surface, are not accessible to immune surveillance in most solid tumors (21). Frequently arising problems of cancer cell recognition and development of the antitumor immune response are due to the low immunogenicity of tumor antigens, their low expression, the lack of HLA and other differentiated antigen expression on the tumor cells surface, and so forth (2, 9, 32). In view of this, the majority of studies dealing with the potential ability of breast tumor antigens to serve as prognostic markers for early detection and monitoring of tumor progression, use cell lines, purified cells, or their lysates (21, 33, 34, 35). However, advanced structured solid tumor includes not only cancer cells, but also stromal, immune, and inflammatory cells and elements, and their vital products. Therefore, we used the PBMC activation by unfractionized tumor tissue for creating an experimental in vitro model similar to in vivo tumor-host interaction, whereas the host responds to the entirety of cellular and noncellular tumor components. On the other hand, the methodology using frozen tumor tissue may introduce a potential degree of variability, related to a heterogeneous not precisely defined composition of the material used. We performed duplicate measurements to overcome part of these variations. Thirdly, the use of peripheral blood allows for periodical evaluations during an extensive pre- and postoperative period, thus allowing the monitoring of long-term effects in BC patients (by use of autologous tumor tissue) and the control of persons with high cancer risk (by use of homologous tumor tissue).

Our observations indicated that there is an essential difference between peripheral mononuclear cells of BC patients and healthy subjects with respect to the overall esterase enzymatic activity. First of all, both mitogenic activation and tumor tissue exposure resulted in an increase of Km, which indicated that this biochemical parameter is probably involved in lymphocyte stimulation. Moreover, a significant difference between cells of BC patients and healthy subjects was clearly demonstrated after the exposure of peripheral cells to tumor tissue; the apparent Km values in BC patients significantly increased, whereas in healthy subjects they did not alter.

Generally, an increase in Km values signifies that the same enzyme-substrate reaction velocity requires a lower substrate concentration. As mentioned, in our measurement system, Km is an apparent parameter, calculated from the fluorescence intensity measurements of fluorescein accumulated by living cells in situ. In contrast to direct enzyme-substrate interaction in vitro when the concentrations of reagents are known, under the present experimental conditions the actual intracellular substrate concentrations remained unknown. We operated only with defined external substrate concentrations. The conversion of substrate concentrations from the extracellular to the intracellular levels depends, primarily, on the active and passive mechanisms of the cell membrane permeability to the substrate, i.e., on the cell membrane condition. Unlike in healthy donor cells, in cells derived from BC patients only, a rapid activation of PBMCs by unfractionized tumor tissue can lead to changes in the cell membrane status and the corresponding decrease in the effective intracellular substrate concentration necessary for the maximal enzyme-substrate interaction.

The Km changes after incubation of the peripheral cells with tumor tissue may be alternatively explained by changes in the intracellular enzyme status, namely, enzyme concentration, conformation, or affinity for the substrate, which may be relevant to carcinogenesis.

Both assumptions can explain, to some extent, the obtained results. There is a need for additional investigations of the mechanisms involved in early activation of circulating blood cells by tumor tissue exposure and of the biopathogenic mediators of such activation.

The possible connection of the total enzymatic activity of esterases in PBMC (assessed in our study via fluorescein accumulation) and BC pathogenesis can be reinforced by the evidence of an indirect relationship between total intracellular esterases activity and chemical protein carbamoylation. The modifications of the total activity of esterases in tumor cells, as well as in the peripheral mononuclear cells, may be related to impairment of protein carbamoylation and the consequent changes in the processes of cellular growth and proliferation (36, 37, 38). It seems possible that carbamoylation-related alterations of macromolecular synthesis in carcinogenesis may lead to the perturbed state of tumor-associated cells and circulating lymphocytes, as well as to a change in receptor expression, suppression of PBMC immune response, and, finally, to the detrimental effects of tumor on the regulatory systems (10, 32, 35, 39, 40). Additionally, the contravention of carbamoylation process may result, for example, in a change of the cytostatic drug toxic effects (41, 42).

Interestingly, the Km changes in breast and colon cancer patients had the same tendencies, which may be evidence common for all solid tumor mechanisms of protein synthesis change, and of the enzymatic reactions independent of the cancer type. The above results make such a conclusion logical and allow us to suggest the present methodology as an additional technique for determining the PBMC immune response, not only in BC, but also in various other types of solid cancer.

The evaluation of the relation between general biochemical characteristics and extensive clinical parameters indicates that in patients with a better clinical-pathological status (lymph node-negative tumors, hormone-receptor preservation, and the absence of Her-2/neu protein overexpression), PBMC exposure to tumor tissue leads to a sharp increase in the Km level as compared with patients with a poorer prognosis. Our observations may present evidence of step-by-step alterations of biochemical processes during cancer development with a partial preservation of normal function in BC patients who exhibit better clinical characteristics.

In connection to a major aspect of this work concerning the character of biochemical reactions in cells incubated with autologous or homologous tissue, it is important to note that the present initial results pose numerous questions regarding the nature and mechanisms of interaction between peripheral lymphocytes and tumor tissues of various origin. The obtained results open a wide field for research concerned with the role of intracellular esterases in lymphocyte activation processes, as well as with specificity of esterase intracellular activity in normal physiological conditions and pathology.

Our results indicate that significant differences are obtained even within statistically small groups, which speaks in favor of our concept. This may present evidence of at least a tendency of increase in Km values after tumor tissue exposure in cancer patients. Finally, based on the results obtained from 61 participants, the following conclusions are suggested.

Firstly, on exposure to tumor tissue, the peripheral blood cell enzymatic reactions in BC patients are markedly different from enzymatic reactions in healthy individuals, based on the classic signs Km and Vmax.

Secondly, higher Km values of tumor tissue-activated PBMCs are associated with a better prognostic status of BC patients.

Finally, the basic characteristics, Km and Vmax, of the enzymatic reactions of live peripheral white blood mononuclear cells can serve as an additional criterion for monitoring and prognosis of BC.

Grant support: Komen Foundation and the Horowitz Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Mordechai Deutsch, The Biophysical Interdisciplinary Jerome Schottenstein Center for the Research and the Technology of the Cellome, Physics Department, Bar Ilan University, Ramat Gan 52900, Israel. Phone: 972-3-534-4675; Fax: 972-3-534-2019; E-mail: rtcellom@mail.biu.ac.il

Fig. 1.

The intracellular enzymatic reaction as monitored by fluorescent intensity of accumulated fluorescein (the ordinate) in individual peripheral blood mononuclear cells in one of the breast cancer patients (infiltrating ductal carcinoma, grade 1, without metastases). A, untreated cells; B, cells incubated with autologous tumor tissue. Each cluster is defined by six fluorescent intensity measurements taken at six time points for the same individual cells (20 cells total) when exposed to the appropriate substrate concentrations that are shown by arrows above (thus, each of the 20 cells was scanned 24 times). The spaces between clusters represent the duration of the staining solutions replacement.

Fig. 1.

The intracellular enzymatic reaction as monitored by fluorescent intensity of accumulated fluorescein (the ordinate) in individual peripheral blood mononuclear cells in one of the breast cancer patients (infiltrating ductal carcinoma, grade 1, without metastases). A, untreated cells; B, cells incubated with autologous tumor tissue. Each cluster is defined by six fluorescent intensity measurements taken at six time points for the same individual cells (20 cells total) when exposed to the appropriate substrate concentrations that are shown by arrows above (thus, each of the 20 cells was scanned 24 times). The spaces between clusters represent the duration of the staining solutions replacement.

Close modal
Fig. 2.

Average Km values in groups with different tumor histopathological grades. A significant difference in Km values of untreated cells (the Untreated cells group) was found between breast cancer patients with high (grade 1, ) and moderately (grade 2, ▪) differentiated tumors (∗, P < 0.0009). The increase of Km values after incubation with tumor tissue (the Tumor tissue treated cells group) is statistically significant (∗∗, P < 0.03) in breast cancer patients with moderately differentiated (grade 2 ▪) tumors, as compared with the healthy donor cells (□). In patients with low differentiated tumor () the increase of average Km value after tumor tissue exposure was not statistically significant. Results (mean) are expressed as substrate concentration (Km) in μm;bars, ±SE. Student’s t test was performed to discriminate between the results obtained in the different groups.

Fig. 2.

Average Km values in groups with different tumor histopathological grades. A significant difference in Km values of untreated cells (the Untreated cells group) was found between breast cancer patients with high (grade 1, ) and moderately (grade 2, ▪) differentiated tumors (∗, P < 0.0009). The increase of Km values after incubation with tumor tissue (the Tumor tissue treated cells group) is statistically significant (∗∗, P < 0.03) in breast cancer patients with moderately differentiated (grade 2 ▪) tumors, as compared with the healthy donor cells (□). In patients with low differentiated tumor () the increase of average Km value after tumor tissue exposure was not statistically significant. Results (mean) are expressed as substrate concentration (Km) in μm;bars, ±SE. Student’s t test was performed to discriminate between the results obtained in the different groups.

Close modal
Fig. 3.

Average Km values in untreated peripheral blood mononuclear cells and in cells incubated with tumor tissue: ▪, breast cancer (BC) patient cells incubated with autologous tumor tissues; , BC patient cells incubated with homologous tumor tissues; and □, healthy donor cells incubated with BC tissues. Results (mean) are expressed in μm; bars, ±SE. Student’s t test was performed to discriminate between the untreated and tumor tissue treated cells (∗, P < 0.05).

Fig. 3.

Average Km values in untreated peripheral blood mononuclear cells and in cells incubated with tumor tissue: ▪, breast cancer (BC) patient cells incubated with autologous tumor tissues; , BC patient cells incubated with homologous tumor tissues; and □, healthy donor cells incubated with BC tissues. Results (mean) are expressed in μm; bars, ±SE. Student’s t test was performed to discriminate between the untreated and tumor tissue treated cells (∗, P < 0.05).

Close modal
Table 1

Clinicopathological characteristics of the examined breast cancer patients

Age (years) <40 3.5
40–49 7.0
50–59 21.5
60–69 18
70–79 32
80+ 10
Cellular characteristics Ductal carcinoma 72
Lobular carcinoma 12
Tubular carcinoma
Ductal carcinoma in situ 36
Tumor size <1.0 29
1.1–2.0 22
2.1–3.0 35
>3.1 17
Axillary lymph nodes status Metastasis negative 72
Metastasis positive 28
Estrogen receptor status Positive 64
Negative 16
No data 20
Progesterone receptor status Positive 56
Negative 24
No data 20
Her-2/neu status Positive 16
Negative 56
No data 28
Ki67 status Positive 64
No data 35
Age (years) <40 3.5
40–49 7.0
50–59 21.5
60–69 18
70–79 32
80+ 10
Cellular characteristics Ductal carcinoma 72
Lobular carcinoma 12
Tubular carcinoma
Ductal carcinoma in situ 36
Tumor size <1.0 29
1.1–2.0 22
2.1–3.0 35
>3.1 17
Axillary lymph nodes status Metastasis negative 72
Metastasis positive 28
Estrogen receptor status Positive 64
Negative 16
No data 20
Progesterone receptor status Positive 56
Negative 24
No data 20
Her-2/neu status Positive 16
Negative 56
No data 28
Ki67 status Positive 64
No data 35
Table 2

The general enzymatic characteristics of PBMCsa in cancer patients and healthy donors

ParametersHealthy donors (n = 23)Breast cancer (n = 28)Colon cancer (n = 10)
Kmm
Untreated 1.73 ± 0.18 1.93 ± 0.24 2.02 ± 0.2
PHA 2.41 ± 0.21 2.52 ± 0.25b 3.22 ± 0.4b
Tumor tissue 1.56 ± 0.12 2.95 ± 0.47b 3.45 ± 0.72b
Vmax (au)
Untreated 633.8 ± 87.9 476.7 ± 99.2 338.9 ± 80.1
PHA 1995.5 ± 360.3b 1094.5 ± 131.8b 513.6 ± 94.8
Tumor tissue 612.5 ± 112.6 722.9 ± 269.1 422.1 ± 96.3
ParametersHealthy donors (n = 23)Breast cancer (n = 28)Colon cancer (n = 10)
Kmm
Untreated 1.73 ± 0.18 1.93 ± 0.24 2.02 ± 0.2
PHA 2.41 ± 0.21 2.52 ± 0.25b 3.22 ± 0.4b
Tumor tissue 1.56 ± 0.12 2.95 ± 0.47b 3.45 ± 0.72b
Vmax (au)
Untreated 633.8 ± 87.9 476.7 ± 99.2 338.9 ± 80.1
PHA 1995.5 ± 360.3b 1094.5 ± 131.8b 513.6 ± 94.8
Tumor tissue 612.5 ± 112.6 722.9 ± 269.1 422.1 ± 96.3
a

PBMC, peripheral blood mononuclear cell; PHA, phytohemagglutinin.

b

P < 0.05 represents the significance of difference between untreated cells and cells incubated with PHA or tumor tissue.

Table 3

The changes of Vmax (au) in the various groups of breast cancer patients depending on the tumor histopathological grade

Untreated cellsTumor tissue treated cellsPhytohemagglutinin activated cells
Well-differentiated tumors 224.9 ± 64.8 254.9 ± 93.7 1071.8 ± 316.9a
Moderately differentiated tumor 648.6 ± 186.3 1111.7 ± 479.8 1124.8 ± 193.9
Low-differentiated tumor 321.5 ± 106.0 303.5 ± 123.7 1109.2 ± 254.9a
Untreated cellsTumor tissue treated cellsPhytohemagglutinin activated cells
Well-differentiated tumors 224.9 ± 64.8 254.9 ± 93.7 1071.8 ± 316.9a
Moderately differentiated tumor 648.6 ± 186.3 1111.7 ± 479.8 1124.8 ± 193.9
Low-differentiated tumor 321.5 ± 106.0 303.5 ± 123.7 1109.2 ± 254.9a
a

P < 0.02 represents the significance of difference between untreated cells and cells incubated with phytohemagglutinin.

Table 4

The general biochemical characteristics in the various groups of breast cancer patients depending on risk factors

Risk factorsMean Kmm) values
PositiveNegative
Untreated cellsTumor tissueP                  aUntreated cellsTumor tissueP                  a
Metastasis 1.74 ± 0.16 1.81 ± 0.37 <0.85 1.68 ± 0.16 3.7 ± 0.67 <0.009
Her-2/neu protein overexpression 1.41 ± 0.27 2.43 ± 0.7 <0.20 1.9 ± 0.18 3.37 ± 0.67 <0.04
Estrogen Rc 1.85 ± 0.16 2.94 ± 0.47 <0.04 1.31 ± 0.24 5.28 ± 2.01 <0.09
Progesterone Rc 2.0 ± 0.17 3.2 ± 0.57 <0.04 1.2 ± 0.21 4.21 ± 1.27 <0.09
Risk factorsMean Kmm) values
PositiveNegative
Untreated cellsTumor tissueP                  aUntreated cellsTumor tissueP                  a
Metastasis 1.74 ± 0.16 1.81 ± 0.37 <0.85 1.68 ± 0.16 3.7 ± 0.67 <0.009
Her-2/neu protein overexpression 1.41 ± 0.27 2.43 ± 0.7 <0.20 1.9 ± 0.18 3.37 ± 0.67 <0.04
Estrogen Rc 1.85 ± 0.16 2.94 ± 0.47 <0.04 1.31 ± 0.24 5.28 ± 2.01 <0.09
Progesterone Rc 2.0 ± 0.17 3.2 ± 0.57 <0.04 1.2 ± 0.21 4.21 ± 1.27 <0.09
a

P represents the significance of difference between untreated cells and cells incubated with tumor tissue.

1
American Cancer Society. .
Cancer facts and figures
, American Cancer Society Atlanta
1998
.
2
Ghadersohi A., Chitta K., Greco W. R., Harvey S., Winston J., Slocum H., Odunsi K., Sood A. K. Tumor antigens and markers for breast and ovarian cancers.
Front. Biosci.
,
7
:
e48
-57,
2002
.
3
McCoy J. L., Rucker R., Petros J. A. Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status.
Breast Cancer Res. Treat.
,
60
:
227
-234,
2000
.
4
Luftner D., Possinger K. Nuclear matrix proteins as biomarkers for breast cancer.
Expert. Rev. Mol. Diagn.
,
2
:
23
-31,
2002
.
5
Le M. G., Arriagada R., Spielmann M., Guinebretiere J. M., Rochard F. Prognostic factor for death after an isolated local recurrence in patients with early-stage breast carcinoma.
Cancer (Phila.)
,
94
:
2813
-2820,
2002
.
6
Voogd A. C., Coebergh J. W., Repelaer van Driel O. J., Roumen R. M., van Beek M. W., Vreugdenhil A., Crommelin M. A. The risk of nodal metastases in breast cancer patients with clinically negative lymph nodes: a population-based analysis.
Breast Can. Res. Treat.
,
62
:
63
-69,
2000
.
7
Ingvarsson S. Molecular genetics of breast cancer progression.
Cancer Biol.
,
9
:
277
-288,
1999
.
8
Boon T., Coulie P. G., van den Eynde B. Tumor antigens recognized by T cells.
Immunol. Today
,
18
:
267
-268,
1997
.
9
Shrivastava P. K. Do human cancers express shared protective antigens? Or the necessity of remembrance of things past?.
Semin. Immunol.
,
8
:
295
-302,
1996
.
10
Whiteside T. L. Signaling defects in T lymphocytes of patients with malignancy.
Cancer Immunol. Immunother.
,
48
:
346
-352,
1999
.
11
Compagni A., Christofori G. Recent advances in research on multistage tumorigenesis.
Br. J. Cancer
,
83
:
1
-5,
2000
.
12
Pettit S. J., Seymour K., O’Flaherty E., Kirby J. A. Immune selection in neoplasia: towards a microevolutionary model of cancer development.
Br. J. Cancer
,
82
:
1900
-1906,
2000
.
13
Halm H. A., Davidson N. E. Apoptosis in the mammary gland and breast cancer.
Endocrine-Related Cancer
,
5
:
199
-211,
1998
.
14
Rahmani H., Deutsch M., Ron I., Gerbat S., Tirosh R., Weinreb A., Chaitchik S., Lalchuk S. Adaptation of the cellscan technique for the SCM test in breast cancer.
Eur. J. Cancer
,
32A
:
1758
-1765,
1996
.
15
Ron I. G., Deutsch M., Tirosh R., Weinreb A., Eisenthal A., Chaitchik S. Fluorescence polarization changes in lymphocyte cytoplasm as a diagnostic test for breast carcinoma.
Eur. J. Cancer
,
31A
:
917
-920,
1995
.
16
Eisenthal A., Marder O., Dotan D., Baron S., Lifschitz-Mercer B., Chaitchik S., Tirosh R., Weinreb A., Deutsch M. Decrease of intracellular fluorescein fluorescence polarization (IFFP) in human peripheral blood lymphocytes undergoing stimulation with phytohemagglutinine (PHA), concanavalin A (ConA), pokeweed mitogen (Pwm) and anti-CD3 antibody.
Biol. Cell
,
86
:
145
-150,
1996
.
17
Kaplan M. R., Trubnikov E., Berke G. Fluorescence depolarization as an early measure of T lymphocyte stimulation.
J. Immunol. Methods
,
201
:
15
-24,
1997
.
18
Sunray M., Zurgil N., Shafran Y., Deutsch M. Determination of individual cell Michaelis-Menten constants.
Cytometry
,
47
:
8
-16,
2002
.
19
Deutsch M., Zurgil N., Kaufman M., Berke G. Fluorescence polarization as an early measure of T-lymphocyte stimulation Kearse K. P. eds. .
Methods in Molecular Biology, Vol. 134: T Cell Protocols: Development and Activation
,
221
-242, Humana Press Totowa, NJ
2000
.
20
Rawal N., Pangburn M. K. C5 convertase of the alternative pathway of complements: kinetic analysis of the free and surface-bound forms of the enzyme.
J. Biol. Chem.
,
273
:
16828
-16835,
1998
.
21
Zier K., Johnson K., Maddux J. M., Sung M., Mandeli J., Eisenbach L., Schwartz M. IFNγ secretion following stimulation with total tumor peptides from autologous human tumors.
J. Immunol. Methods
,
241
:
61
-68,
2000
.
22
Sontag W. A comparative kinetic study on the conversion of fluoresceindiacetate to fluorescein in living cells and in vitro.
,
14
:
1
-12,
1977
.
23
Sontag W. Changes of fluoresceindiacetate-hydrolisis and transport in mammalian cells after ultra-violet- and gamma irradiation.
,
14
:
13
-20,
1977
.
24
Deutsch M., Kaufman M., Shapiro H., Zurgil N. Analysis of enzyme kinetics in individual living cells utilizing fluorescence intensity and polarization measurements.
Cytometry
,
39
:
36
-44,
2000
.
25
Bedner E., Melamed M. R., Darzynkiewicz Z. Enzyme kinetic reactions and fluorochrome uptake rates measured in individual cells by Laser Scanning Cytometry.
Cytometry
,
33
:
1
-9,
1998
.
26
Augsten K., Guttner J. FDA-hydrolysis for the fluorometrical evidence of a cell membrane alteration in peritoneal macrophages.
Acta Histochem.
,
52
:
79
-87,
1975
.
27
Fishman-Lobell J., Tsui P., Reddy M., DiPrinzio R., Eichman C., Sweet R. W., Truneh A. CD4 mAb induced apoptosis of peripheral T cells: multiparameter subpopulation analysis by flow cytometry using Attractord.
J. Immunol. Methods
,
257
:
71
-82,
2001
.
28
Watson J. V., Dive C. Enzyme kinetics.
Methods Cell Biol.
,
41
:
469
-507,
1994
.
29
Schmalz G., Netuschil L. A modification of the cell culture agar diffusion test using fluoresceindiacetate staining.
J. Biomed. Mater. Res.
,
19
:
653
-661,
1985
.
30
Gelskey S., Brecx M., Netuschil L., McDonald L., Brownstone E., Stoddart M. Vital fluorescence: a new measure of periodontal treatment effect.
J. Can. Dent. Assoc.
,
59
:
615
-618,
1993
.
31
Bruheim P., Eimhjellen K. Effect of non-ionic surfactants on the uptake and hydrolysis of fluoresceindiacetate by alkane-oxidizing bacteria.
Can. J. Microbiol.
,
46
:
387
-390,
2000
.
32
Hansen M. H., Nielsen H., Ditzel H. J. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells.
,
98
:
12659
-12664,
2001
.
33
Nair S. K., Boczkowski D., Snyder D., Gilboa E. Antigen presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
Eur. J. Immunol.
,
27
:
589
-597,
1997
.
34
Zhao X., Wei Y. Q., Peng Z. L. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells.
Immunol. Investig.
,
30
:
33
-45,
2001
.
35
Head J. F., Elliott R. L., McCoy J. L. Evaluation of lymphocyte immunity in breast cancer patients.
Breast Cancer Res. Treat.
,
26
:
77
-88,
1993
.
36
Yano K. Carbamoylation reactions of N-methyl-N′-aryl-N-nitrosoureas and corresponding phenyl isocyanates to 5′-amino-5′-deoxythymidine: importance of carbamoylation in mouse skin carcinogenic processes.
Carcinogenesis (Lond.)
,
13
:
699
-702,
1992
.
37
Hu J. J., Luke A., Chellani M., Zirvi K. A., Lea M. A. pH-related effects of sodium cyanate on macromolecular synthesis and tumor cell division.
Biochem. Pharmacol.
,
37
:
2259
-2266,
1988
.
38
Lea M. A. Effects of carbamoylating agents on tumor metabolism.
Crit. Rev. Oncol. Hematol.
,
7
:
329
-371,
1987
.
39
Wiltschke C., Krainer M., Budinsky A. C., Berger A., Muller C., Zeillinger R., Speiser P., Kubista E., Eibl M., Zeilinski C. C. Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective study.
Br. J. Cancer
,
71
:
1292
-1296,
1995
.
40
Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G. R., Schobert I., Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host.
,
92
:
11810
-3,
1995
.
41
Dive C., Workman P., Watson J. V. Inhibition of intracellular esterases by antitumor chloroethylnitrosoureas. Measurement by flow Cytometry and correlation with molecular carbamoylation activity.
Biochem. Pharmacol.
,
37
:
3987
-3993,
1988
.
42
Dive C., Workman P., Watson J. V. Inhibition of intracellular esterases by the antitumor imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.
Cancer Chemother. Pharmacol.
,
25
:
149
-155,
1989
.